Edgewise Therapeutics, Inc. (EWTX) News
Filter EWTX News Items
EWTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EWTX News Highlights
- For EWTX, its 30 day story count is now at 3.
- Over the past 7 days, the trend for EWTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest EWTX News From Around the Web
Below are the latest news stories about EDGEWISE THERAPEUTICS INC that investors may wish to consider to help them evaluate EWTX as an investment opportunity.
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024BOULDER, Colo., December 19, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am PT (1:30 pm ET). |
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy CommunityBOULDER, Colo., December 18, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the launch of an educational website dedicated to the Becker muscular dystrophy (Becker) community: www.beckermusculardystrophy.com. This is the first website solely focused on providing Becker-specific resources to help individuals and caregivers better understand the disease, learn different approaches to care and stay up to date on advocacy partne |
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDABOULDER, Colo., November 30, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker) and Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne. EDG-5506 is an investigational orally administered small molecule designed to |
Speculator’s Watch List: 7 Stocks Ripe for a Short-Squeeze WindfallAlthough betting against the bears is risky, the rewards for targeting short-squeeze stocks can also be stratospheric. |
Edgewise Therapeutics Inc (EWTX) Reports Q3 2023 Financial Results and Business ProgressAdvancements in Muscular Dystrophy and Cardiomyopathy Trials Accompany Financial Developments |
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsBOULDER, Colo., November 09, 2023--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2023 and recent business highlights. |
Edgewise Therapeutics to Present at Upcoming Investor ConferencesBOULDER, Colo., November 08, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, announced today that members of its senior management team will participate in the following upcoming investor conferences: |
Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023BOULDER, Colo., November 01, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from November 11 - 13. EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardi |
Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)BOULDER, Colo., October 26, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced an expansion of their clinical development program of EDG-5506, an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne. The Company is initiating FOX, a new Phase 2 placebo-controlled trial in children and adolescent boys with Duchenne who have been previous |